Professional Documents
Culture Documents
Market Outlook 19th October 2011
Market Outlook 19th October 2011
Market Outlook 19th October 2011
India Research
October 19, 2011
Dealers Diary
The Indian markets are poised for a positive opening tracing firm opening in most of the Asian markets in the early market trade. The domestic benchmark indices fell second straight day yesterday and touched one-week closing low as sentiments weakened due to weakness in global shares as uncertainty persisted over the speedy resolution of eurozone crises. Global cues remained fragile over concerns about the global economic outlook after Moody's warned that it may put a negative outlook on France's Aaa credit rating and China reported a slowdown in third quarter GDP. European bourses ended on a mixed note. However, US indices closed higher following strong earnings reports from Bank of America and upbeat data on homebuilder confidence. On the domestic front, investors remain cautious and will closely watch out for the 2QFY2012 corporate earnings as profitability remains a key issue. Poor quarterly results by IT majors TCS and HCL Technologies have also impacted the sentiments. In addition, re-ignition of fears that the debt crisis in Europe has more legs to play out will serve as an overhang.
Domestic Indices BSE Sensex Nifty MID CAP SMALL CAP BSE HC BSE PSU BANKEX AUTO METAL OIL & GAS BSE IT Global Indices Dow Jones NASDAQ FTSE Nikkei Hang Seng Straits Times Shanghai Com
Chg (%) (1.6) (1.6) (1.2) (1.0) (0.6) (0.8) (1.4) (1.7) (1.7) (1.2) (3.7) Chg (%) 1.6 1.6 (0.5) (1.6) (4.2) (2.0) (2.3)
(Pts) (276.8) (80.8) (75.1) (68.6) (37.3) (56.6) (160.7) (148.5) (194.6) (107.2) (208.0) (Pts) 42.5 (26.4) (137.7) (797.5) (54.3) (56.9)
(Close) 16,748 5,038 6,114 6,854 5,855 7,352 10,970 8,840 11,120 8,550 5,462 (Close) 2,657 5,410 8,742 18,077 2,725 2,383
180.1 11,577
Markets Today
The trend deciding level for the day is 16,747/5,035 levels. If NIFTY trades above this level during the first half-an-hour of trade then we may witness a further rally up to 16,826 16,903 / 5,060 5,082 levels. However, if NIFTY trades below 16,747/5,035 levels for the first half-an-hour of trade then it may correct up to 16,670 16,592 / 5,013 4,989 levels.
Indices SENSEX NIFTY S2 16,592 4,989 S1 16,670 5,013 R1 16,826 5,060 R2 16,903 5,082
News Analysis
2QFY2012 Result Reviews Hero MotoCorp, HCL Tech., Petronet LNG, CRISIL 2QFY2012 Result Previews HDFC Bank, Hindustan Zinc, Crompton Greaves, Infotech Enterprises, Alembic Pharmaceuticals
Refer detailed news analysis on the following page
Gainers / Losers
Patni Computer ING Vysya Bank Coal India Torrent Power Hindustan Copp.
(13.5) (8.6) (7.7) (5.7) (4.5) Sebi Registration No: INB 010996539
Petronet LNG
Petronet LNG reported a stellar performance for 2QFY2012. The companys net sales increased by 75.5% yoy to `5,367cr, driven by increased sales volumes as well as realization. The companys total volumes increased by 35.4% yoy to 135TBTU, while average realization increased by 29.7% yoy to `397/mmbtu. Average cost, on the other hand, also increased by 29.1% yoy to `356/mmbtu. Further, other expenditure increased by 278.1% yoy to `99cr. Hence, EBITDA increased by 64.5% yoy to `448cr. Other income increased by 8.2% yoy to `20cr, while tax rate decreased to 30.8% in 2QFY2012, compared to 32.3% in 2QFY2011. Hence, net profit grew by 98.5% yoy to `260cr. Currently, the stock is under review
October 19, 2011
CRISIL 3QCY2011
CRISIL registered strong top-line growth in 3QCY2011. The companys net sales grew by 38.3% yoy to `220cr on the back of strong growth of 48.0% yoy in its research segment to `111cr (`75cr). The rating segment also registered modest 14.3% yoy growth to `84cr (`73cr). CRISIL reported a 281bp yoy expansion in OPM to 38.1% (35.3%), largely on account of a decline in staff cost as a percentage of sales, which declined by 227bp yoy. Net profit declined by 20.2% yoy to `60cr (`75cr). The sharp decline in PAT was due to lower other income during the quarter, which declined by 88.1% yoy to `5cr from `44cr in 3QCY2010. The company has announced another round of buy back of shares. The company will be purchasing shares directly from the market with a maximum price of `1,000/share and up to an aggregate amount of `80cr. With current market capitalization of `5,956cr, the company will only be able to buy back 1.3% (assuming CMP of `839/share) of the total shares, which will not have any significant impact on our estimates. We continue to maintain our Neutral recommendation on the stock. We will be coming with an updated report post management interaction.
Hindustan Zinc
Hindustan Zinc is slated to announce its 2QFY2012 results. The companys top line is expected to register 22.2% yoy growth to `2,643cr on account of higher sales volume and realisation. However, the companys EBITDA margin is expected to contract by 200bp yoy to 50.0% on account of higher costs. Nevertheless, the bottom line is expected to grow by 33.3% yoy to `1,265cr. We maintain our Buy view on the stock with a target price of `156.
Crompton Greaves
Crompton Greaves is scheduled to announce its 2QFY2012 results. The company is expected to report muted top-line growth of 6.0% yoy to `2,542cr, attributable to the power system segment, which has remained a drag since the past few quarters. The companys EBITDA margin is expected to witness a steep contraction of ~490bp yoy to 9% on account of high input costs and pricing pressures. Interest cost is also expected to post a two-fold increase on a yoy basis. Lower revenue coupled with operational weakness is expected to drive down PAT by whopping 45.8% yoy to `115.8cr. Currently, we continue to remain Neutral on the stock.
Infotech Enterprises
Infotech Enterprises is slated to announce its 2QFY2012 results. We expect the company to post revenue of US$80.1mn, up 3.4% qoq, majorly led by volume growth. In INR terms, revenue is expected to come in at `366cr, up 5.6% qoq. EBITDA margin is expected to expand by 106bp qoq to 13.6%. PAT is expected to come in at `29cr. We maintain our Neutral view on the stock.
Alembic Pharmaceuticals
For 2QFY2012, Alembic Pharmaceuticals net sales are expected to be come in at `317cr. The company is expected to report OPM of 14.0%. Net profit is expected to come in at ~`23.4cr. At the CMP, the stock is trading at 8.4x FY2012E and 6.9x FY2013E earnings. We maintain our Buy recommendation on the stock with a target price of `65.
Corporate News
Tata Motors plans bus, truck assembly lines in Latin America, South East Asia Coal India Ltd. asks government to lower FY2012 production target to 448MT Essar Energy to supply 300MW to Bihar from Tori-I project SAT orders Sahara to refund `24,029cr in six weeks
Source: Economic Times, Business Standard, Business Line, Financial Express, Mint
Results Calendar
19/10/2011 Rallis, Crompton Greaves, HDFC Bank, Infotech Enterprises, Hind. Zinc, Indraprasth Gas Bajaj Auto, Exide Industries, FAG Bearings, Thermax, UltraTech Cement, IDBI Bank, Yes Bank, Hexaware, KPIT Cummins, D B 20/10/2011 Corp, Indoco Remedies United Phosphorus, Hind. Const., Larsen & Toubro, Federal Bank, Indiabulls Fin., Asian Paints, Godrej Consumer, NIIT, HT 21/10/2011 Media, PVR, JSW Steel , GIPCL, Idea Cellular Blue Star, Suzlon Energy, Axis Bank, Bank of Maharashtra, Syndicate Bank, Jagran Prakashan, Sarda Energy, Siyaram Silk Mills, 22/10/2011 Grasim Inds, Power Grid Corpn 24/10/2011 Jyoti Structures, Sadbhav Engg., Union Bank, ITC, Sterlite Inds, GAIL, Titan Inds.
E-mail: research@angelbroking.com
Website: www.angelbroking.com
DISCLAIMER
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and its affiliates may have investment positions in the stocks recommended in this report.